Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
McKinsey
Harvard Business School
Johnson and Johnson

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

QUZYTTIR Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Quzyttir patents expire, and what generic alternatives are available?

Quzyttir is a drug marketed by JDP and is included in one NDA. There are five patents protecting this drug.

This drug has five patent family members in five countries.

The generic ingredient in QUZYTTIR is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-three suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.

Summary for QUZYTTIR
International Patents:5
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 1
Formulation / Manufacturing:see details
DailyMed Link:QUZYTTIR at DailyMed
Drug patent expirations by year for QUZYTTIR
Recent Clinical Trials for QUZYTTIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
JDP Therapeutics, Inc.Phase 2
TerSera TherapeuticsPhase 2

See all QUZYTTIR clinical trials

Pharmacology for QUZYTTIR

US Patents and Regulatory Information for QUZYTTIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Jdp QUZYTTIR cetirizine hydrochloride SOLUTION;INTRAVENOUS 211415-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for QUZYTTIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0663828 C300085 Netherlands   Start Trial PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium   Start Trial PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Baxter
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.